Mechanisms of neutrophil apoptosis in uremia and relevance of the Fas (APO-1, CD95)/Fas ligand system.
The regulation of neutrophil apoptosis in chronic renal failure (CRF) has not been clearly defined. The Fas/FasL system is an important apoptotic regulatory pathway in a wide variety of cells. Fas is a widely expressed cell surface protein that transduces an apoptotic signal after interaction with its natural ligand FasL. In contrast to the extensive tissue distribution of Fas, constitutive expression of FasL is relatively limited. We examined Fas and FasL expression by neutrophils in healthy subjects, patients with CRF, and patients on hemodialysis (HD) and peritoneal dialysis (PD). Fas expression was significantly higher among patients with CRF compared with control subjects, HD patients, and PD patients. FasL expression was significantly higher among patients with CRF compared with control subjects. At 24 h, neutrophil apoptosis was higher among patients with CRF compared with control subjects. Furthermore, high-neutrophil Fas expression was paralleled by a higher sensitivity to Fas-mediated apoptosis. There was a strong correlation between Fas-stimulated apoptosis and creatinine clearance as well as Fas expression. Finally, we found that uremic serum increased the expression of neutrophil-associated Fas and FasL proteins, when compared with normal serum. Further studies are under way to examine the regulation of this pathway in the uremic environment.
Jaber
B L
BL
Division of Nephrology, Department of Medicine, Tupper Research Institute, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA. bjaber@lifespan.org
Perianayagam
M C
MC
Balakrishnan
V S
VS
King
A J
AJ
Pereira
B J
BJ
D000328:Adult; D000368:Aged; D017209:Apoptosis / Q000502:physiology*; D015153:Blotting, Western; D002478:Cells, Cultured; D003404:Creatinine / Q000378:metabolism; D053222:Fas Ligand Protein; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics / Q000502:physiology*; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009504:Neutrophils / Q000473:pathology*; D010530:Peritoneal Dialysis; D006435:Renal Dialysis; D014158:Transcription, Genetic; D014511:Uremia / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D019014:fas Receptor / Q000235:genetics / Q000502:physiology*
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D019014:fas Receptor; D003404:Creatinine